Coherus Oncology, Inc. Deferred Revenue
Coherus Oncology, Inc. (CHRS) had Deferred Revenue of $669.00 thousand as of 2017-03-31, per its 10-Q filed 2017-05-08.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2018-03-08
- 2017-03-31: Deferred Revenue, Current $669.00K.
- 2016-12-31: Deferred Revenue, Current $892.00K.
- 2016-09-30: Deferred Revenue, Current $1.38M.
- 2016-06-30: Deferred Revenue, Current $61.26M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2017-03-31 | $669.00K 10-Q · filed 2017-05-08 |
| 2016-12-31 | $892.00K 10-K · filed 2018-03-08 |
| 2016-09-30 | $1.38M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $61.26M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $49.63M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $49.62M 10-K · filed 2017-03-14 |
| 2015-09-30 | $28.85M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $31.00M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $22.80M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $22.80M 10-K · filed 2016-02-29 |
| 2014-09-30 | $25.18M 10-Q · filed 2014-12-15 |
| 2013-12-31 | $14.28M 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |